Trumpflation Positions Cohen & Steers Poorly Due To Real Estate And Preferred Focus
Cohen & Steers (CNS) faces AUM declines due to asset depreciation in REITs and preferred shares amid persistent inflation affecting bond markets. This could be a portent for incoming outflows or inflow deceleration. At any rate, the macro changes don't favour long-duration asset ETFs that CNS focuses on. Despite positive net inflows, revenue growth was offset by rising expenses, resulting in flat EPS.
Cohen & Steers, Inc. (CNS) Q4 2024 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q4 2024 Earnings Conference Call January 23, 2025 10:00 AM ET Company Participants Brian Heller - Senior Vice President & Deputy Corporate Counsel Raja Dakkuri - Chief Financial Officer Joe Harvey - Chief Executive Officer Jeff Palma - Head of our Multi-Asset Solutions Conference Call Participants John Dunn - Evercore ISI Ben Rubin - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Fourth Quarter and Full Year 2024 Earnings Conference Call.
Corero Network Security to Present at Microcap Conference
MARLBOROUGH, MA / ACCESSWIRE / December 12, 2024 / Corero Network Security (LSE:CNS)(OTCQX:DDOSF), the distributed denial of service (DDOS) protection specialists is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM study Quarter marked by pipeline expansion with in-license of TPI 287, a late stage novel potential blood brain barrier permeable abeotaxane for treatment of brain malignancies HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter 2024 ended September 30, 2024. "Our team has made nothing short of transformational advancements throughout 2024.
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share. The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions.
Cohen & Steers Stock : A Buy With Results Beat And Positive Outlook
Cohen & Steers' Q3 2024 results exceeded expectations, with revenue up 9.4% YoY and non-GAAP adjusted EPS up 13.5% YoY. Significant AUM growth and a return to positive net inflows drove the strong financial performance for Cohen & Steers in the recent quarter. CNS' near-term prospects are favorable, with expected revenue and earnings growth due to increased investor real estate allocations and the company's private real estate AUM expansion.
Cohen & Steers, Inc. (CNS) Q3 2024 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q3 2024 Earnings Conference Call October 17, 2024 10:00 AM ET Company Participants Brian Heller - Senior Vice President and Corporate Counsel Jon Cheigh - Chief Investment Officer Joseph Harvey - Chief Executive Officer and President Raja Dakkuri - Chief Financial Officer Conference Call Participants John Dunn - Evercore ISI Benjamin Rubin - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Third Quarter 2024 Earnings Conference Call.
